Elicio Therapeutics Inc ELTX.O:
ELICIO THERAPEUTICS ANNOUNCES POSITIVE RECOMMENDATION BY IDMC TO CONTINUE ELI-002 7P RANDOMIZED PHASE 2 STUDY IN PANCREATIC CANCER WITHOUT MODIFICATIONS TO FINAL ANALYSIS
ELICIO THERAPEUTICS INC - FINAL DFS ANALYSIS EXPECTED IN Q4 2025
ELICIO THERAPEUTICS INC - CASH RUNWAY EXTENDS INTO Q1 2026
ELICIO THERAPEUTICS INC - IDMC CONFIRMS SAFETY PROFILE OF ELI-002 7P
Source text: ID:nGNX8mRDWT
Further company coverage: ELTX.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.